Assessment of the Long-term Efficacy of Moderately Hypofractionated Neoadjuvant Radiotherapy Soft Tissue Sarcoma in the Limbs or Trunk Wall

This trial aims to assess the long-term efficacy of moderately hypofractionated neoadjuvant radiotherapy for soft tissue sarcoma in the limbs or trunk wall. The primary outcome is local disease control, assessed by the cumulative incidence of progression/recurrence. After informed consent has been obtained and eligibility criteria have been checked, a baseline assessment will be performed followed by the experimental treatment: intensity-modulated radiotherapy with a moderately hypofractionated regimen consisting in 15 fractions of 2.7 Gy administered over 3 weeks. a follow-up assessment wil

Trial Details

NCT ID
NCT07507773
Phase
PHASE2
Sponsor
Centre Oscar Lambret
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Moderately hypofractionated neoadjuvant radiotherapy
Locations (sample)
  • Lille, France|50.63391,3.05512

Key Eligibility Criteria

  • Patient aged ≥ 18 years ;
  • Localised sarcoma of a limb, the root of a limb, or the trunk wall ;
  • Histologically confirmed diagnosis of soft tissue sarcoma regardless of the grade ;
  • Diagnosis biopsy performed at Centre Oscar Lambret, with specimen available for translational research ;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →